Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mel...

Por Qiu, Rong, Capuano, George, Meininger, Gary
Publicado no J Clin Transl Endocrinol (2014)

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program

Por Erondu, Ngozi, Desai, Mehul, Ways, Kirk, Meininger, Gary
Publicado no Diabetes Care (2015)

Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes

Por Qiu, Rong, Balis, Dainius, Capuano, George, Xie, John, Meininger, Gary
Publicado no Diabetes Ther (2016)

A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures

Por Patel, Charmi A., Bailey, Robert A., Vijapurkar, Ujjwala, Meininger, Gary, Blonde, Lawrence
Publicado no BMC Health Serv Res (2016)

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects

Por Heerspink, Hiddo J. L., Desai, Mehul, Jardine, Meg, Balis, Dainius, Meininger, Gary, Perkovic, Vlado
Publicado no J Am Soc Nephrol (2017)

Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis

Por Sinclair, Alan J., Bode, Bruce, Harris, Stewart, Vijapurkar, Ujjwala, Shaw, Wayne, Desai, Mehul, Meininger, Gary
Publicado no J Am Geriatr Soc (2016)

Reliability and Feasibility of Methods to Quantitatively Assess Peripheral Edema

Por Brodovicz, Kimberly G., McNaughton, Kristin, Uemura, Naoto, Meininger, Gary, Girman, Cynthia J., Yale, Steven H.
Publicado em 2009

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

Por Watts, Nelson B., Bilezikian, John P., Usiskin, Keith, Edwards, Robert, Desai, Mehul, Law, Gordon, Meininger, Gary
Publicado no J Clin Endocrinol Metab (2016)

Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus

Por Weir, Matthew R., Januszewicz, Andrzej, Gilbert, Richard E., Vijapurkar, Ujjwala, Kline, Irina, Fung, Albert, Meininger, Gary
Publicado no J Clin Hypertens (Greenwich) (2014)

Efficacy and Safety of Canagliflozin in Type 2 Diabetes Patients of Different Ethnicity

Por Davidson, Jaime A., Aguilar, Richard, Lavalle González, Fernando J., Trujillo, Angelina, Alba, Maria, Vijapurkar, Ujjwala, Meininger, Gary
Publicado no Ethn Dis (2016)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India

Por Prasanna Kumar, K. M., Mohan, Viswanathan, Sethi, Bipin, Gandhi, Pramod, Bantwal, Ganapathi, Xie, John, Meininger, Gary, Qiu, Rong
Publicado no Indian J Endocrinol Metab (2016)

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial

Por Schernthaner, Guntram, Gross, Jorge L., Rosenstock, Julio, Guarisco, Michael, Fu, Min, Yee, Jacqueline, Kawaguchi, Masato, Canovatchel, William, Meininger, Gary
Publicado em 2013

Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

Por Sinclair, Alan, Bode, Bruce, Harris, Stewart, Vijapurkar, Ujjwala, Mayer, Cristiana, Fung, Albert, Shaw, Wayne, Usiskin, Keith, Desai, Mehul, Meininger, Gary
Publicado em 2014

Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes

Por Meininger, Gary E., Scott, Russell, Alba, Maria, Shentu, Yue, Luo, Edmund, Amin, Himal, Davies, Michael J., Kaufman, Keith D., Goldstein, Barry J.
Publicado em 2011

Effects of canagliflozin on body weight and relationship to HbA(1c) and blood pressure changes in patients with type 2 diabetes

Por Cefalu, William T., Stenlöf, Kaj, Leiter, Lawrence A., Wilding, John P. H., Blonde, Lawrence, Polidori, David, Xie, John, Sullivan, Daniel, Usiskin, Keith, Canovatchel, William, Meininger, Gary
Publicado no Diabetologia (2015)

Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial

Por Fulcher, Greg, Matthews, David R., Perkovic, Vlado, de Zeeuw, Dick, Mahaffey, Kenneth W., Weiss, Robert, Rosenstock, Julio, Capuano, George, Desai, Mehul, Shaw, Wayne, Vercruysse, Frank, Meininger, Gary, Neal, Bruce
Publicado no Diabetes Ther (2015)

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial

Por Neal, Bruce, Perkovic, Vlado, Matthews, David R., Mahaffey, Kenneth W., Fulcher, Greg, Meininger, Gary, Erondu, Ngozi, Desai, Mehul, Shaw, Wayne, Vercruysse, Frank, Yee, Jacqueline, Deng, Hsiaowei, de Zeeuw, Dick
Publicado no Diabetes Obes Metab (2017)

Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co‐transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four...

Por Wang, Lu, Voss, Erica A., Weaver, James, Hester, Laura, Yuan, Zhong, DeFalco, Frank, Schuemie, Martijn J., Ryan, Patrick B., Sun, Don, Freedman, Amy, Alba, Maria, Lind, Joan, Meininger, Gary, Berlin, Jesse A., Rosenthal, Norman
Publicado no Pharmacoepidemiol Drug Saf (2019)